secwatch.observer — SEC 8-K summary
======================================

Issuer:     Absci Corp (ABSI)
CIK:        0001672688
Form:       8-K
Filed at:   2025-03-18T23:59:59+00:00
Accession:  0001628280-25-013455
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Absci Q4 revenue $0.7M, net loss $29M; pipeline advances and AMD collaboration
------------------------------------------------------------------------------

- Q4 revenue $0.7M (vs $0.3M YoY); net loss $29.0M vs $23.5M.
- Cash & investments $112.4M; sufficient into H1 2027; gross cash burn ~$72M in FY2024.
- ABS-101 anti-TL1A to enter Phase 1 in H1 2025; interim data expected H2 2025.
- AMD strategic collaboration includes $20M equity investment; AI drug discovery workloads.
- Expects to sign one or more drug creation partnerships in 2025, including with Large Pharma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672688/000162828025013455/0001628280-25-013455-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672688/000162828025013455/absc-20250318.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-013455

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer